Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has included SZJ0107 tablets, developed by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd., in the “Care Plan Extension” pilot project for encouraging innovative drug R&D for rare diseases, targeting spinocerebellar ataxia (SCA), the agency announced in a formal inclusion notice dated Sept 4, 2026.

Program Snapshot

Attribute	Detail
Program	Care Plan Extension (Rare Disease Innovative Drug R&D Incentive Pilot)
Product	SZJ0107 Tablets
Applicant	Anhui Sanzhijian Pharmaceutical Technology Co., Ltd.
Indication	Spinocerebellar ataxia (SCA)
Notice type	Formal pilot inclusion (not a public consultation)
Issuing body	Center for Drug Evaluation (CDE), NMPA
Date	Sept 4, 2026

Clinical Context

Spinocerebellar ataxia refers to a group of hereditary neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connections, leading to worsening coordination of gait, speech and limb movements. More than 40 genetic subtypes have been identified, with SCA3 (Machado-Joseph disease) the most prevalent form in China. No disease-modifying therapy is currently approved for SCA—treatment remains supportive—and the condition is listed in China’s official rare disease catalog, with estimated prevalence of roughly 3 to 6 per 100,000. The absence of any approved therapy and the progressive, disabling nature of the disease place SCA among the highest-unmet-need areas in neurology.

Market Impact Analysis

Unlike proposal-stage listings that open a public comment window, this notice confirms SZJ0107’s formal inclusion in the Care Plan Extension pilot—meaning the asset immediately qualifies for the program’s incentive package, which typically encompasses enhanced regulatory communication, rolling data submissions and potential priority pathways for rare disease candidates.

For Anhui Sanzhijian, a regional pharmaceutical technology company, the designation elevates a niche neurology asset into China’s premier rare disease fast-track framework, improving both development economics and partnering visibility. SCA represents a strategically underserved space: global developers have historically deprioritized it due to small patient populations and genetically heterogeneous trial designs, yet recent advances in genetic and targeted therapeutic approaches are reviving interest worldwide. By channeling a domestic SCA candidate into the pilot, CDE is signaling intent to build indigenous capability in rare neurodegenerative diseases rather than rely on imported therapies.

The inclusion also adds momentum to the Care Plan Extension cohort itself, demonstrating that the program is actively admitting CNS and neurodegenerative indications beyond its initial focus areas, which could encourage additional submissions from small and mid-cap Chinese biotechs pursuing orphan neurology assets.

Forward-Looking Statement

Industry observers expect SZJ0107 to advance clinical development under the pilot’s enhanced regulatory support, with the formal inclusion potentially compressing trial-to-review timelines if the program generates positive efficacy and safety data in SCA populations. Progress toward registration would mark a potential first-in-class outcome for spinocerebellar ataxia in China, establishing proof-of-concept for the Care Plan Extension in hereditary ataxias and opening pathways for related neurodegenerative rare disease candidates. The inclusion further reinforces China’s strategic push to localize rare disease drug innovation and expand treatment options for patients currently limited to supportive care. Further details on SZJ0107’s development stage and trial plans are expected to emerge from the applicant as the program advances.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/074dea77e97b316fc1c783cc0091937b

Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding MRO-001HS capsules, developed by Maiba Pharmaceutical (Hangzhou) Co., Ltd., to the “Care Plan Extension” pilot for encouraging innovative drug R&D for rare diseases, targeting amyotrophic lateral sclerosis (ALS), with a public comment deadline of Sept 11, 2026.

Program Snapshot

Attribute	Detail
Program	Care Plan Extension (Rare Disease Innovative Drug R&D Incentive Pilot)
Product	MRO-001HS Capsules
Applicant	Maiba Pharmaceutical (Hangzhou) Co., Ltd.
Indication	Amyotrophic lateral sclerosis (ALS)
Comment deadline	Sept 11, 2026
Contact	zhaona@cde.org.cn

Clinical Context

Amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease or motor neuron disease, is a progressive neurodegenerative disorder that destroys upper and lower motor neurons, leading to muscle atrophy, paralysis and typically death from respiratory failure within three to five years of diagnosis. Therapeutic options remain severely limited—riluzole and edaravone offer only modest slowing of progression, while newer agents such as tofersen address narrow genetic subgroups. ALS is included in China’s official catalog of rare diseases, where the prevalence of roughly 3 to 5 per 100,000 implies a patient population well over 100,000 nationwide, most of whom lack access to disease-modifying therapy.

Market Impact Analysis

The proposed inclusion signals CDE’s expanding use of its rare disease incentive framework to pull innovative candidates into a fast-track regulatory environment. The Care Plan Extension builds on the original Care Plan pilot by broadening eligibility and reinforcing a package of development incentives—enhanced preclinical and clinical communication channels, rolling review of data submissions, and potential priority pathways—that materially de-risk ALS programs for small and mid-cap biotechs.

For Maiba Pharmaceutical, a Hangzhou-based developer, the pilot listing positions MRO-001HS alongside a growing cohort of China-originated CNS and rare disease assets seeking differentiated regulatory support rather than competing head-to-head in crowded oncology indications. The economics of ALS drug development are challenging—small trial populations, heterogeneous progression and limited pricing power—yet the designation improves both the regulatory timeline and the asset’s partnering profile, a critical consideration for biotechs courting global license deals.

The one-week comment window, shorter than typical CDE public consultations, suggests regulators view the submission as aligned with the pilot’s urgent mandate to accelerate therapies for life-threatening rare diseases with few existing options, rather than a contested listing.

Forward-Looking Statement

Industry observers expect MRO-001HS to progress into pivotal-stage clinical development under the pilot’s enhanced regulatory support, with the Care Plan Extension designation potentially compressing the timeline from clinical trials to NDA acceptance by several quarters if the program generates positive data. Successful development in ALS could establish a proof-of-concept for the extended incentive framework in neurodegenerative rare diseases, encouraging additional filings targeting motor neuron disorders and related indications. The pilot also reinforces China’s strategic push to localize rare disease innovation, reducing dependence on imported therapies for conditions like ALS. Final inclusion in the pilot is anticipated following the Sept 11 comment deadline, barring substantive objections.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/3efc47502efbabbd6d4231e145718966